A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)
Recruiting now · Phase 1
Conditions studied: Amyotrophic Lateral Sclerosis
In brief
The primary objective of this dose-finding study is to evaluate the safety, tolerability and pharmacodynamics of single dose of INS1202 via IT administration in participants ≥ 18 to \<80 years of age with ALS who carry superoxide dismutase type 1 (SOD1) mutations or harbor no known ALS-related genetic mutation.
Key facts
- Study ID
- NCT07290062
- Run by
- Insmed Gene Therapy LLC
- People needed
- 23
- Starts
- 2026-01-09
- Expected to finish
- 2030-03-31
- Last updated by the study team
- 2026-07-06
Who can join
Age: 18 and older, up to 79. Sex: any. Healthy volunteers: not accepted.
Where it is running
- USA004 — La Jolla, California, United States (enrolling)
- USA002 — Palo Alto, California, United States (enrolling)
- USA001 — Columbia, Missouri, United States (enrolling)
- USA007 — Columbus, Ohio, United States (enrolling)
- USA006 — Philadelphia, Pennsylvania, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.